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Abstract
Background: In blood purification therapies for critical care, there are no guidelines for selecting modalities of the
treatment or for determining the treatment schedule, treatment time, and operating conditions, such as dialysate
flow rate (QD) and filtration flow rate (QF). In this paper, the solute removal characteristics of blood purification for
critical care and the optimal operating conditions for individual patients are discussed from the viewpoint of kinetic
modeling.
Method: An in vitro study using an aqueous solution involving several marker solutes was performed.
Results: From a result of the continuous hemodialysis (CHD) experiments, the QD should be required at least twice
the patient’s blood flow rate (QB) for sufficient removal of small molecular substances. CHD is of limited use for the
removal of middle-sized molecules. During the continuous hemofiltration (CHF) experiments in the post-dilution
mode, the maximum QF value can be determined as about 1/4 of the QB because of the existence of the formed
elements. In summary of the continuous hemodiafiltration (CHDF) experiments, the QF is about 1/4 of QB value and
the QD should be set up at least twice the QB value.
The determination of adequate operating conditions for individual patients can be summarized from a kinetic
modeling viewpoint:
1. Determination of the targeted solute according to the patient’s state.
2. Determination of the generation rate of the targeted solute by collecting spent dialysate and/or filtrate.
3. Determination of the minimal requirement treatment dose from the actual and targeted solute concentration
levels.
4. Choice of treatment modality and determination of the treatment time according to the clearance value.
Conclusions: Measurement of the removed amount of solute by collecting the spent dialysate and/or filtrate is
recommended to maintain an adequate plasma level of the targeted solute of patients, who often have unstable
states. The adequate operating conditions for each patient can be determined from a kinetic modeling viewpoint.
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Background
In blood purification therapies for critical care, there are
no guidelines for selecting modalities, such as continuous
hemodialysis (CHD), continuous hemofiltration (CHF),
and continuous hemodiafiltration (CHDF), or for deter-
mining the treatment schedule, treatment time, and the
operating conditions, such as the blood flow rate (QB), di-
alysate flow rate (QD), and filtration flow rate (QF), for in-
dividual patients. Instead, these conditions are determined
according to the experience of the patient’s doctor based
on trial and error.
In this paper, the solute removal characteristics of
blood purification for critical care and the optimal oper-
ating conditions for individual patients are discussed
from the viewpoint of kinetic modeling.
Solute removal characteristics of blood purification
devices
Blood purification therapy for critical care requires some
specific conditions, compared with maintenance dialysis
therapy for chronic kidney disease patients:
(1) A lower QB is needed because the patient often has
an unstable hemodynamic state and is unlikely to
have an arteriovenous fistula (AVF) or
arteriovenous graft (AVG).
(2) A longer treatment time is required because of the
lower QB.
(3) The patients are often actively bleeding.
Blood purification devices for critical care require the
following characteristics:
(1) A compact size with a smaller priming volume
(PV)
(2) A lower degradation for device performance
(3) A lower pressure drop on the blood side to avoid
clotting in the device
Based on these requirements, a relatively small size of
hollow fiber membrane device with a membrane surface
area (A) of 0.1–1.1 m2, a PV of 12–87 mL, and a slightly
larger inner diameter of the hollow fiber (220 μm) has
been developed and used clinically.
To determine the solute removal characteristics of
CHD, CHDF, and CHF, an in vitro study using an
aqueous solution and a cellulose triacetate membrane
filter, FB-50H, with an A of 0.5 m2 (Nipro Corp,
Osaka, Japan) was performed [1]. Reverse osmosis
(RO) water including solutes was used for the blood
side solution in all the experiments, and RO water
was used for the dialysate in the HD and HDF exper-
iments. Urea (60 Da), creatinine (113 Da), vitamin B12
(1350 Da), and inulin (5200 Da) were chosen as
marker solutes in this study. Samples of the solute
concentrations at the inlet and outlet of the blood
side (CBI and CBO) and at the outlet side of the di-
alysate (CDO) for CHD or CHDF and at the filtrate
side (CF) for CHF were obtained. All the experi-
ments were performed using a multipurpose dialysis
machine (ACH-07; Asahikasei Medical Co. Ltd.,
Tokyo, Japan).
The solute clearances were calculated using the
following equations:
(1) Blood side clearance (KB) for all experiments:
KB ¼ CBI−CBOCBI QBI ð1Þ
(2) Dialysate side clearance (KD) for the CHD and
CHDF experiments:
KD ¼ CDOCBI QDO ð2Þ
(3) Filtrate side clearance (KF) for the CHF
experiments:
KF ¼ CFCBI QF ¼ SC⋅QF ð3Þ
SC is the sieving coefficient of the solute.
The left side of Fig. 1 shows the effects of QB on KD in
the CHD experiments under a QD of 48.3 mL/min with
no filtration [1]. The KD values for urea and creatinine
increased with the QB. The right side of Fig. 1 shows the
effects of QD on KB in the CHD experiments under a QB
of 50.0 mL/min with no filtration [1]. The KB value in-
creased steeply with QB under a QD < 100 mL/min and
reached a plateau level at a QD of over 200 mL/min. Al-
though a QD of 500–1500 mL/h was chosen from an
economical viewpoint in a typical clinical treatment, QD
should be required at least twice the QB for the sake of
obtaining sufficient KB value. On the other hand, the
vitamin B12 and inulin KB values were less than half of
the urea and creatinine KB values. Thus, CHD is of lim-
ited use for the removal of such middle-sized molecules.
Figure 2 shows the effect of QF on KF in the CHF
experiments using a post-dilution mode under a QB
of 50.0 mL/min with no dialysate flow [1]. The KF
value increased proportionally with the QF. From
Eq. 3, the slope of the proportional line indicates the
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SC value of the solute to the membrane device. Be-
cause the solute SC value is almost unchanged for a
device, the KF value strongly depends on the QF
(namely, the amount of replacement fluid, VR). In the
post-dilution mode, the maximum QF value can be
determined as about 1/4 of the QB because of the ex-
istence of formed elements, such as erythrocytes.
Figure 3 shows the effects of QD and QF on KB in
the CHDF experiments using a post-dilution mode
under a QB of 50.0 mL/min [1]. As shown on the left
side of Fig. 3, the relationship between the KB and
QD values was similar to that observed in the CHD
experiments. The KB values for vitamin B12 and inu-
lin, however, slightly increased as a result of convect-
ive transport arising from a QF of 10.4 mL/min. On
the other hand, as shown on the right side of Fig. 3,
a high efficiency of solute removal was obtained using
both diffusive and convective transport in HDF using
the post-dilution mode.
In summary, the QF is about 1/4 of the QB value, and
the QD should be set at least twice the QB value during
CHDF treatment.
Optimal operating conditions for blood purification
therapies for critical care
Determining the operating conditions for individual pa-
tients is very important for clinical treatment. An
adequate VR and QD can be determined from a kinetic
modeling viewpoint. In this paper, the adequate parame-
ters were determined using urea kinetic modeling [2].
If a 1-compartment model is used to describe urea
transport during continuous renal replacement therapies
(CRRT) such as CHD, CHF, and CHDF, the plasma sol-
ute concentration (C) can be described as follows:
C ¼ G
K av
¼ GT
Kt
¼ G
K
 
 T
t
 
¼ GT
V
 
 V
Kt
 
ð4Þ
where the symbols G and Kav denote the urea generation
rate and the time-averaged urea clearance, respectively.
The C can be defined as G divided by Kav. After the Kt
and T in this equation, C can be described as GT/V di-
vided by Kt/V. The symbols t and T represent the
Fig. 1 Effects of blood flow rate (QB) and dialysate flow rate (QD) on solute clearance (K) in the CHD experiments [1]
Fig. 2 Effects of filtration flow rate (QB) on solute clearance (K) in the
CHF experiments [1]
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treatment time and the treatment cycle (for example,
24 h). The V denotes the urea distribution volume.
Material balance equations for urea can be applied as
follows:
MG ¼ GT ð5Þ
MR ¼ Kt  Cav; ð6Þ
where the symbols MG and MR denote the amount of
urea generated and removed by CRRT, respectively. Cav
means the time-averaged concentration of urea. The re-
lations among MG, MR, and Cav can be described using
the following 3 patterns:
(1) When MG >MR for T, the C increases because the
generation rate is superior to the removal rate.
(2) When MG =MR for T, the C remains unchanged
because the generation rate is equal to the removal
rate.
(3) When MG <MR for T, the C decreases because the
removal rate is superior to the generation rate.
The change in the urea concentration, ΔC, can be de-
scribed as follows:
ΔC ¼ MG−MR
V
ð7Þ
By substituting Eqs. 5 and 6 into Eq. 7, the following
equations can be obtained:
MG ¼ MR þ VΔC ð8Þ
G ¼ MR þ VΔCð Þ=T ð9Þ
As shown in Eqs. 8 and 9, the urea generation rate G
can be estimated by measuring the amount of urea
removed by the CRRT treatment MR and the change in
the urea concentration ΔC for T.
As an example, we supposed that a patient weighing
50 kg (BW) received a CRRT treatment and the BUN
level of the patient increased from 80 to 100 mg/dL
for 24 h. If the MR was obtained by collecting the
spent dialysate and filtrate during the treatment and
estimated as 5000 mg, the G value of the patient can
be calculated as follows using Eq. 9 and supposing V
(L) to be 60 % of the BW (kg):
G ¼ 5000þ 50 0:6ð Þ  10 100−80ð Þ
60 24
¼ 7:6 mg=min
We can determine the optimal operating conditions of
the CRRT treatment for the patient using urea kinetic
modeling.
The amount of urea generated during 24 h can be esti-
mated as follows:
GT ¼ 7:6 60 24 ¼ 11; 000 mg ¼ 11 g
If the target of the BUN level is supposed to be
80 mg/dL, the minimal requirement of the treatment
dose can be calculated using Eqs. 5 and 6 as follows:
Kt ¼ 11; 000=80 ¼ 137:5 dL ¼ 13:8 L
From this estimation, the optimal operating conditions
for several blood purification therapies can be deter-
mined as follows:
(1) CHF: The minimal amount of replacement fluid
(VR) is 14 L.
(2) CHD: When the dialyzer clearance (K) is assumed
to be 30 mL/min, the treatment time can be
calculated as follows:
Fig. 3 Effects of dialysate flow rate (QD) and filtration flow rate (QF) on solute clearance (K) in the CHDF experiments [1]
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13:8 1000=30 ¼ 458 min ¼ 7:6 h:
(3) CHDF: When the dialyzer clearance (K) is assumed
to be 40 mL/min, the treatment time can be
calculated as follows:
13:8 1000=40 ¼ 343 min ¼ 5:7 h:
Although urea removal in CRRT therapies was men-
tioned above, CHDF and CHF (which are based on con-
vective transport by filtration) are effective for the
removal of relatively large molecules, such as some kinds
of cytokines.
The determination of adequate operating conditions
for individual patients who receive blood purification
therapy for critical care can be summarized from a kin-
etic modeling viewpoint as follows:
1. Determination of the targeted solute according to
the patient’s state.
2. Determination of the generation rate of the targeted
solute by collecting spent dialysate and/or filtrate.
3. Determination of the minimal requirement
treatment dose from the actual and targeted solute
concentration levels.
4. Choice of treatment modality and determination of
the treatment time according to the clearance value
K.
4-1 In CHF, the replacement volume VR can be
determined as VR = Kt. The filtration flow rate
QF, which is identical to K, can be estimated as
15–30 % of the blood flow rate QB. The
treatment time t can be determined by Kt/K
(=VR/QF).
4-2 In CHD, the dialysate flow rate QD should be set
at least twice the QB. The t can be determined
by Kt/K.
4-3 In CHDF, the QF and QD should be shared
according to the targeted solute. The QD should
be set at least twice the QB. The t can be
determined by Kt/K.
Conclusions
Measurement of the removed amount of solute by col-
lecting the spent dialysate and/or filtrate is recom-
mended to maintain an adequate plasma level of the
targeted solute in critical care patients, who often have
unstable states.
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